• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Eiger Begins Enrollment in LIMT-2 Phase 3 Study of Peginterferon Lambda

    PRNEWSWIRE

    Triple drug combination shows promise in Covid-19 treatment

    CLINICALTRIALSARENA

    Bausch Health initiates VIRAZOLE trial in Covid-19 patients

    CLINICALTRIALSARENA

    Bausch Health begins clinical study in Canada evaluating Virazole in combo

    PHARMABIZ

    Can old drugs take down a new coronavirus?

    C&EN

    Biogen Idec`s Plegridy (Peginterferon beta-1a) Receives Supplemental Approval In US

    AbbVie reports 99% cure rate for pan-genotypic Hep C therapy

    PHARMA TIMES

    Japan Grants Priority Review to AbbVie`s Investigational Regimen

    DDDMAG

    Aviragen takes a tumble as RSV drug fails mid-stage trial

    FIERCE BIOTECH

    SMC OKs four new therapies for NHS use in Scotland

    PHARMATIMES

    Enanta reports positive results from phase 3 CERTAIN-1 study

    PHARMABIZ

    Mylan Signs Sub-license Agreement with the Medicines Patent Pool

    PR NEWSWIRE

    Recent Success in HCV Treatment Brings Relief to Patients

    DRUG DEVELOPMENT

    AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK

    PR NEWSWIRE

    Merck says its Zepatier showed better efficacy, safety compared with competition

    PHARMAFILE

    Australia bets $1B on pricey hepC drug in broad effort to eradicate the disease

    FIERCE PHARMA

    U.S. FDA approves Gilead`s hepatitis C drug for expanded use

    REUTERS

    AbbVie nears launch of Viekira into crowded Japan HCV battle

    FIERCE PHARMA ASIA

    Merck drug could offer Hep C cure to kidney disease patients

    PHARMATIMES

    AbbVie hepatitis C cocktail succeeds in late-stage study

    REUTERS

    Abbvie Reports Positive Phase 3 Study Results from all-Oral Treatment for Hepatitis C in Japan

    PHARMABIZ

    Valeant Pharmaceuticals North America LLC , Ongoing Class II recall of Virazole (Ribavirin for Inhalation Solution, USP), Sterile Lyophilized For Administration by Aerosol Inhalation Only, Rx only, Contents: Four 6 g vials, 100 mL, Distributed by: Valeant Pharmaceuticals North America, Bridgewater, NJ 08807 USA, NDC 0187-0007-14. because of Non-Sterility: Valeant`s laboratory observed a positive microbial contamination of Virazole lot 340353F, during testing at the 12 month stability pull.

    FDA

    NICE Backs New Hepatitis C Treatments

    PMLIVE

    Valeant Pharmaceuticals North America LLC Issues Voluntary Recall of Virazole® (ribavirin powder for solution) in the United States

    PR NEWSWIRE

    CA Panel: Gilead`s Harvoni Cost-Effective At $95K, But Only Affordable At Half the Price

    FIERCEPHARMA

    Class Action Lawsuit Challenges the Exorbitant Pricing of Gilead`s Hepatitis-C Drug Sovaldi

    PRNEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.